Expression of miR-199a-3p in human adipocytes is regulated by free fatty acids and adipokines

Molecular Medicine Reports

Volumn 14, Issue 2, 2016, Pages 1180-1186

  Gu, Nan ^a   You, Lianghui ^a   Shi, Chunmei ^a   Yang, Lei ^a   Pang, Lingxia ^a   Cui, Xianwei ^a   Ji, Chenbo ^a   Zheng, Wen ^b   Guo, Xirong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Yancheng Women and Children's Hospital and Health Institute   (China)

Author keywords

Adipocytes; Adipokines; FFAs; MiR 199a 3p; Obesity

Indexed keywords

ADIPOCYTOKINE; FATTY ACID; INTERLEUKIN 6; LEPTIN; MICRORNA; MICRORNA 199A 3P; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FAT DROPLET; INTERLEUKIN 1BETA; MIRN199 MICRORNA, HUMAN; TUMOR NECROSIS FACTOR;

ADIPOCYTE; ARTICLE; BODY MASS; CELL DIFFERENTIATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; HYPERTENSION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MESENCHYMAL STEM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION; ADIPOSE TISSUE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; CELL DIFFERENTIATION; CELLS, CULTURED; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1BETA; LEPTIN; LIPID DROPLETS; MICRORNAS; OBESITY; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978431593     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5379     Document Type: Article

References (55)

1. Van Gaal LF, Mertens IL and De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880, 2006.
2. Dorresteijn JA, Visseren FL and Spiering W: Mechanisms linking obesity to hypertension. Obes Rev 13: 17-26, 2012.
3. Bell JA, Kivimaki M and Hamer M: Metabolically healthy obesity and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies. Obes Rev 15: 504-515, 2014.
4. Cummings DE and Schwartz MW: Genetics and pathophysiology of human obesity. Annu Rev Med 54: 453-471, 2003.
5. Morigny P, Houssier M, Mouisel E and Langin D: Adipocyte lipolysis and insulin resistance. Biochimie, 2015 (Epub ahead of print).
6. Fasshauer M and Blüher M: Adipokines in health and disease. Trends Pharmacol Sci 36: 461-470, 2015.
7. Bluher M: Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab 27: 163-177, 2013.
8. Guilherme A, Virbasius JV, Puri V and Czech MP: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367-377, 2008.
9. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell 116: 281-297, 2004.
10. Kusakabe R and Inoue K: Developmental regulation and evolution of muscle-specific microRNAs. Semin Cell Dev Biol 47-48: 9-16, 2015.
11. Alvarez-Garcia I and Miska EA: MicroRNA functions in animal development and human disease. Development 132: 4653-4662, 2005.
12. Sun M, Liu XH, Li JH, Yang JS, Zhang EB, Yin DD, Liu ZL, Zhou J, Ding Y, Li SQ, et al: MiR-196a is upregulated in gastric cancer and promotes cell proliferation by downregulating p27(kip1). Mol Cancer Ther 11: 842-852, 2012.
13. Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK and Beretta L: Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology 63: 864-879, 2016.
14. Thomas H: Diabetes: Enterovirus dysregulates islet miRNAs. Nat Rev Endocrinol 12: 2, 2016.
15. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, et al: MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 279: 52361-52365, 2004.
16. Chen L, Dai YM, Ji CB, Yang L, Shi CM, Xu GF, Pang LX, Huang FY, Zhang CM and Guo XR: MiR-146b is a regulator of human visceral preadipocyte proliferation and differentiation and its expression is altered in human obesity. Mol Cell Endocrinol 393: 65-74, 2014.
17. Gerin I, Bommer GT, McCoin CS, Sousa KM, Krishnan V and MacDougald OA: Roles for miRNA-378/378 in adipocyte gene expression and lipogenesis. Am J Physiol Endocrinol Metab 299: E198-E206, 2010.
18. Martinelli R, Nardelli C, Pilone V, Buonomo T, Liguori R, Castanò I, Buono P, Masone S, Persico G, Forestieri P, et al: miR-519d overexpression is associated with human obesity. Obesity (Silver Spring) 18: 2170-2176, 2010.
19. Williams MD and Mitchell GM: MicroRNAs in insulin resistance and obesity. Exp Diabetes Res 2012: 484696, 2012.
20. Zhu H and Leung SW: Identification of microRNA biomarkers in type 2 diabetes: A meta-analysis of controlled profiling studies. Diabetologia 58: 900-911, 2015.
21. Nesca V, Guay C, Jacovetti C, Menoud V, Peyot ML, Laybutt DR, Prentki M and Regazzi R: Identification of particular groups of microRNAs that positively or negatively impact on beta cell function in obese models of type 2 diabetes. Diabetologia 56: 2203-2012, 2013.
22. Shi C, Zhang M, Tong M, Yang L, Pang L, Chen L, Xu, Chi X, Hong Q, Ni Y, et al: miR-148a is associated with obesity and modulates adipocyte differentiation of mesenchymal stem cells through Wnt signaling. Sci Rep 5: 9930, 2015.
23. Yang L, Shi CM, Chen L, Pang LX, Xu GF, Gu N, Zhu LJ, Guo XR, Ni YH and Ji CB: The biological effects of hsa-miR-1908 in human adipocytes. Mol Biol Rep 42: 927-935, 2015.
24. Wellen KE, Fucho R, Gregor MF, Furuhashi M, Morgan C, Lindstad T, Vaillancourt E, Gorgun CZ, Saatcioglu F and Hotamisligil GS: Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cel 129: 537-548, 2007.
25. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M and Fasshauer M: Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289: E586-E590, 2005.
26. Shi C, Zhu L, Chen X, Gu N, Chen L, Zhu L, Yang L, Pang L, Guo X, Ji C and Zhang C: IL-6 and TNF-induced obesity-related inflammatory response through transcriptional regulation of miR-146b. J Interferon Cytokine Res 34: 342-348, 2014.
27. Neville MJ, Collins JM, Gloyn AL, McCarthy MI and Karpe F: Comprehensive human adipose tissue mRNA and microRNA endogenous control selection for quantitative real-time-PCR normalization. Obesity (Silver Spring) 19: 888-892, 2011.
28. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
29. Leal VO and Mafra D: Adipokines in obesity. Clin Chim Acta 419: 87-94, 2013.
30. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri L: MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70: 5184-5193, 2010.
31. Gao Y, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri L: CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. Sci Rep 5: 11365, 2015.
32. Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, et al: The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget 6: 11342-11856, 2015.
33. Minna E, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, et al: miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Oncotarget 5: 2513-2528, 2014.
34. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P and Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13: 4279-4295, 2002.
35. Gesta S, Tseng YH and Kahn CR: Developmental origin of fat: Tracking obesity to its source. Cell 131: 242-256, 2007.
36. Boeuf S, Klingenspor M, Van Hal NL, Schneider T, Keijer J and Klaus S: Differential gene expression in white and brown preadipocytes. Physiol Genomics 7: 15-25, 2001.
37. Bluher M and Mantzoros CS: From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century. Metabolism 64: 131-145, 2015.
38. Jéquier E: Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 967: 379-388, 2002.
39. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E and Flier JS: Role of leptin in the neuroendocrine response to fasting. Nature 382: 250-252, 1996.
40. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, et al: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295, 1996.
41. Müller G, Ertl J, Gerl M and Preibisch G: Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 272: 10585-10593, 1997.
42. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS and Lazar MA: The hormone resistin links obesity to diabetes. Nature 409: 307-312, 2001.
43. Chen BH, Song Y, Ding EL, Roberts CK, Manson JE, Rifai N, Buring JE, Gaziano JM and Liu S: Circulating levels of resistin and risk of type 2 diabetes in men and women: Results from two prospective cohorts. Diabetes Care 32: 329-334, 2009.
44. Sheng CH, Di J, Jin Y, Zhang YC, Wu M, Sun Y and Zhang GZ: Resistin is expressed in human hepatocytes and induces insulin resistance. Endocrine 33: 135-143, 2008.
45. Akira S, Taga T and Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 54: 1-78, 1993.
46. Lai Y and Dong C: Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol 28: 181-188, 2016.
47. Hotamisligil GS, Shargill NS and Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993.
48. Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Douvdevani A and Gelman S: Raised interleukin-6 levels in obese patients. Obes Res 8: 673-675, 2000.
49. Eder K, Baffy N, Falus A and Fulop AK: The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 58: 727-736, 2009.
50. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46: 3-10, 1997.
51. Gustafson B, Gogg S, Hedjazifar S, Jenndahl L, Hammarstedt A and Smith U: Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am J Physiol Endocrinol Metab 297: E999-E1003, 2009.
52. Boden G: Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 18: 139-143, 2011.
53. Pei YF, Zhang L, Liu Y, Li J, Shen H, Liu YZ, Tian Q, He H, Wu S, Ran S, et al: Meta-analysis of genome-wide association data identifies novel susceptibility loci for obesity. Hum Mol Genet 23: 820-830, 2014.
54. Maier VH, Melvin DR, Lister CA, Chapman H, Gould GW and Murphy GJ: v-and t-SNARE protein expression in models of insulin resistance: Normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2 and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats. Diabetes 49: 618-625, 2000.
55. Helenius K, Yang Y, Alasaari J and Mäkelä TP: Mat1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipocyte differentiation. Mol Cell Biol 29: 315-323, 2009.